Chemed (CHE) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemed Corporation  (NYSE: CHE)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare

Chemed's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Chemed in the third quarter 2026?
Chemed Corporation achieved a return on average equity (ROE) of 32.1 % in its third quarter 2026, this is above CHE's average return on equity of 27.13%.
Chemed Corporation shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $880 million

ROE has advanced compared to 29.45% in the second quarter 2026, due to net income growth.

Within the Healthcare Facilities industry 3 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 450 to 495.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change -19.99 % -30.7 % -28.24 % -12.47 % -
Y / Y Net Income Change 11.54 % 28.98 % -7.6 % -15.02 % -15.23 %
Net Income (TTM) in Millions 282 275 260 265 279
Return On Equity (TTM) 32.1 % 29.45 % 25.33 % 23.92 % 24.37 %
CHE's Total Ranking # 495 # 450 # 437 # 161 #
Equity (TTM) in Millions 861 831 848 979 1,077
Seq. Equity Change 3.72 % -2.06 % -13.42 % -9.03 % -10.16 %
Seq. Net Income Change 5.83 % 2.11 % -13.61 % 19.48 % 22.37 %

Back to CHE Management Effectiveness >> CHE's 5 Years Annual ROE >> Compare CHE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 4
Sector # 54
Overall # 495

Return On Equity Statistics
High Average Low
40.74 %
27.13 %
13.68 %
(Dec 31 2020)   (Jun 30 2017)





CHE Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 979 1,119 1,108 799 623
Y / Y Equity Change -12.47 % 1 % 38.71 % 28.15 % -30.84 %
Net Income in Millions 265 302 273 250 269
Y / Y Net Income Change -12.17 % 10.82 % 9.17 % -7.05 % -15.94 %
Return On Equity 27.08 % 26.99 % 24.6 % 31.25 % 43.09 %

Back to CHE Management Effectiveness >> CHE's 5 Years Annual ROE >> Compare CHE ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 27.08 % compared to the prior year.


More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CHE's' Return on Equity at Yahoo Finance
CHE's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CHE's Competitors
Subscribers only: Roe for Chemed's Suppliers
Subscribers only: Return On Equity for CHE's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Exelixis Inc   85.83 %
Amgen Inc   85.59 %
Eli Lilly And Company  83.65 %
Rigel Pharmaceuticals Inc  73.94 %
Idexx Laboratories Inc  71.18 %
Tenet Healthcare Corp  57.13 %
Aurinia Pharmaceuticals Inc   51.92 %
Nurix Therapeutics Inc   49.34 %
Carlisle Companies Incorporated  44.18 %
Bristol myers Squibb Company  43.83 %
Zevra Therapeutics Inc   38.02 %
Dexcom Inc   36.56 %
Rallybio Corporation  36.35 %
Caredx Inc   34.08 %
Chemed Corporation  32.10 %
Illumina Inc   31.45 %
Transmedics Group Inc   28.74 %
Acadia Pharmaceuticals Inc   28.03 %
Pro dex Inc   26.91 %
Sotera Health Company  26.41 %
Pacs Group Inc   25.65 %
Standard Biotools Inc   25.58 %
Resmed Inc   25.50 %
Bioventus Inc   24.60 %
Encompass Health Corporation  24.08 %
Iradimed Corporation  23.90 %
Corcept Therapeutics Inc  22.88 %
Msa Safety Inc  21.79 %
Lantheus Holdings Inc   21.72 %
Iqvia Holdings Inc   21.40 %

Date modified: 2026-10-30T13:05:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.